Anti-HER2 Immunoconjugates Targeting Inaccessible Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering antibodies and immune adjuvants are inadequate for accessing inaccessible tumors, limiting treatment options for cancer patients.
Innovation Solution
Development of immunoconjugates comprising an anti-HER2 antibody conjugated to 8-phenyl-2-aminobenzazepine derivatives, which allows for targeted delivery and enhanced therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional delivery methods are used for antibodies and immune adjuvants, then the treatment process is simple, but the ability to reach inaccessible tumors is limited
Solution Approach 1:
The patent combines antibodies and immune adjuvants into a single immunoconjugate molecule, where the antibody component provides tumor targeting capability while the adjuvant component enhances immune response. This merging allows the delivery system to reach inaccessible tumors through the antibody's targeting ability while maintaining a relatively simple overall structure that does not require complex delivery mechanisms.
Solution Approach 2:
The linker component serves as an intermediary between the antibody and adjuvant, enabling their stable association while allowing controlled release of the adjuvant at the target site. This intermediary structure facilitates tumor penetration and immune activation without requiring complex external delivery systems.
2Adaptability or versatility
If standard antibody therapy is used, then the treatment approach is straightforward, but treatment options for cancer patients are limited
Solution Approach 1:
By merging antibody-based tumor targeting with adjuvant-based immune activation in a single molecular construct, the patent creates a dual-function therapeutic that expands treatment options for cancer patients. This combination therapy approach provides both direct tumor targeting and enhanced immune response stimulation without requiring separate administration of multiple complex therapies.
Solution Approach 2:
The immunoconjugate design provides multi-functionality by integrating tumor targeting, immune activation, and controlled drug release capabilities into a single therapeutic agent. This universal platform can be applied to various cancer types by selecting appropriate antibody-target pairs and adjuvant components, thereby expanding treatment options without proportionally increasing regimen complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The immunoconjugates enable effective treatment of cancer by facilitating targeted delivery of anti-HER2 antibodies to tumors, improving treatment outcomes for cancer patients.
Implementation Method 1
an anti-HER2 antibody construct that specifically recognizes and binds HER2
Implementation Method 2
comprising an anti-HER2 antibody construct that is covalently bonded to an adjuvant moiety via a linker
Data Source
AI summary
The invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-phenyl-2-aminobenzazepine derivatives. The invention also provides 8-phenyl-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.